400 related articles for article (PubMed ID: 26645051)
21. Alternative Lengthening of Telomeres in Pediatric High-Grade Glioma and Therapeutic Implications.
Umaru B; Sengupta S; Senthil Kumar S; Drissi R
Cancers (Basel); 2023 Jun; 15(12):. PubMed ID: 37370681
[TBL] [Abstract][Full Text] [Related]
22. Mechanisms that drive telomere maintenance and recombination in human cancers.
Sobinoff AP; Pickett HA
Curr Opin Genet Dev; 2020 Feb; 60():25-30. PubMed ID: 32119936
[TBL] [Abstract][Full Text] [Related]
23. Telomere maintenance and tumorigenesis: an "ALT"ernative road.
Stewart SA
Curr Mol Med; 2005 Mar; 5(2):253-7. PubMed ID: 15974880
[TBL] [Abstract][Full Text] [Related]
24. TCGA Pan-Cancer Genomic Analysis of Alternative Lengthening of Telomeres (ALT) Related Genes.
Armendáriz-Castillo I; López-Cortés A; García-Cárdenas J; Guevara-Ramírez P; Leone PE; Pérez-Villa A; Yumiceba V; Zambrano AK; Guerrero S; Paz-Y-Miño C
Genes (Basel); 2020 Jul; 11(7):. PubMed ID: 32708340
[TBL] [Abstract][Full Text] [Related]
25. A human cell line that maintains telomeres in the absence of telomerase and of key markers of ALT.
Cerone MA; Autexier C; Londoño-Vallejo JA; Bacchetti S
Oncogene; 2005 Nov; 24(53):7893-901. PubMed ID: 16116482
[TBL] [Abstract][Full Text] [Related]
26. Telomere Maintenance Pathway Activity Analysis Enables Tissue- and Gene-Level Inferences.
Nersisyan L; Simonyan A; Binder H; Arakelyan A
Front Genet; 2021; 12():662464. PubMed ID: 33897770
[TBL] [Abstract][Full Text] [Related]
27. Telomere Maintenance Mechanisms in Cancer.
Gaspar TB; Sá A; Lopes JM; Sobrinho-Simões M; Soares P; Vinagre J
Genes (Basel); 2018 May; 9(5):. PubMed ID: 29751586
[TBL] [Abstract][Full Text] [Related]
28. [Telomere Recombination in Normal Mammalian Cells].
Zhdanova NS; Rubtsov NB
Genetika; 2016 Jan; 52(1):14-23. PubMed ID: 27183789
[TBL] [Abstract][Full Text] [Related]
29. Telomere Length Maintenance and Its Transcriptional Regulation in Lynch Syndrome and Sporadic Colorectal Carcinoma.
Nersisyan L; Hopp L; Loeffler-Wirth H; Galle J; Loeffler M; Arakelyan A; Binder H
Front Oncol; 2019; 9():1172. PubMed ID: 31750255
[No Abstract] [Full Text] [Related]
30. Alternative lengthening of telomeres in mammalian cells.
Henson JD; Neumann AA; Yeager TR; Reddel RR
Oncogene; 2002 Jan; 21(4):598-610. PubMed ID: 11850785
[TBL] [Abstract][Full Text] [Related]
31. Association of mutant TP53 with alternative lengthening of telomeres and favorable prognosis in glioma.
Chen YJ; Hakin-Smith V; Teo M; Xinarianos GE; Jellinek DA; Carroll T; McDowell D; MacFarlane MR; Boet R; Baguley BC; Braithwaite AW; Reddel RR; Royds JA
Cancer Res; 2006 Jul; 66(13):6473-6. PubMed ID: 16818615
[TBL] [Abstract][Full Text] [Related]
32. Selective Elimination of Osteosarcoma Cell Lines with Short Telomeres by Ataxia Telangiectasia and Rad3-Related Inhibitors.
Goncalves T; Zoumpoulidou G; Alvarez-Mendoza C; Mancusi C; Collopy LC; Strauss SJ; Mittnacht S; Tomita K
ACS Pharmacol Transl Sci; 2020 Dec; 3(6):1253-1264. PubMed ID: 33344901
[TBL] [Abstract][Full Text] [Related]
33. Telomerase reverse transcriptase expression protects transformed human cells against DNA-damaging agents, and increases tolerance to chromosomal instability.
Fleisig HB; Hukezalie KR; Thompson CA; Au-Yeung TT; Ludlow AT; Zhao CR; Wong JM
Oncogene; 2016 Jan; 35(2):218-27. PubMed ID: 25893297
[TBL] [Abstract][Full Text] [Related]
34. Telomerase- and alternative telomere lengthening-independent telomere stabilization in a metastasis-derived human non-small cell lung cancer cell line: effect of ectopic hTERT.
Brachner A; Sasgary S; Pirker C; Rodgarkia C; Mikula M; Mikulits W; Bergmeister H; Setinek U; Wieser M; Chin SF; Caldas C; Micksche M; Cerni C; Berger W
Cancer Res; 2006 Apr; 66(7):3584-92. PubMed ID: 16585183
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of telomere length maintenance mechanisms in adrenocortical carcinoma.
Else T; Giordano TJ; Hammer GD
J Clin Endocrinol Metab; 2008 Apr; 93(4):1442-9. PubMed ID: 18198226
[TBL] [Abstract][Full Text] [Related]
36. Telomere lengthening in telomerase-negative cells: the ends are coming together.
Scheel C; Poremba C
Virchows Arch; 2002 Jun; 440(6):573-82. PubMed ID: 12070595
[TBL] [Abstract][Full Text] [Related]
37. Telomere uncapping and alternative lengthening of telomeres.
Cesare AJ; Reddel RR
Mech Ageing Dev; 2008; 129(1-2):99-108. PubMed ID: 18215414
[TBL] [Abstract][Full Text] [Related]
38. Xrcc3 and Nbs1 are required for the production of extrachromosomal telomeric circles in human alternative lengthening of telomere cells.
Compton SA; Choi JH; Cesare AJ; Ozgür S; Griffith JD
Cancer Res; 2007 Feb; 67(4):1513-9. PubMed ID: 17308089
[TBL] [Abstract][Full Text] [Related]
39. Targeting ALT: the role of alternative lengthening of telomeres in pathogenesis and prevention of cancer.
Bollmann FM
Cancer Treat Rev; 2007 Dec; 33(8):704-9. PubMed ID: 17933469
[TBL] [Abstract][Full Text] [Related]
40. Alternative lengthening of telomeres phenotype in malignant vascular tumors is highly associated with loss of ATRX expression and is frequently observed in hepatic angiosarcomas.
Liau JY; Tsai JH; Yang CY; Lee JC; Liang CW; Hsu HH; Jeng YM
Hum Pathol; 2015 Sep; 46(9):1360-6. PubMed ID: 26190196
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
